TAKEDA PHARMACEUTICAL CO LTD - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: 10%+ Owner
Signature: /s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
Issuer symbol: XLO
Transactions as of: 21 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 21 Oct 2021, 20:40:37 UTC
Previous filing: 21 Apr 2022
Next filing: 26 Oct 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XLO	Series B Preferred Stock							21 Oct 2021	Common Stock	1,248,180		See explanation	F1, F2, F3
holding	XLO	Series C Preferred Stock							21 Oct 2021	Common Stock	226,941		See explanation	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of the Issuers preferred stock are expected to convert on a one-for-one basis into the number of shares of the Issuers common stock, par value $0.0001 per share (Common Stock), shown in Column 3 immediately upon the closing of the Issuers initial public offering without payment of additional consideration. These shares of the Issuers preferred stock have no expiration date.
F2	This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc.
F3	Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of the 1,248,180 Series B Preferred Stock held by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
F4	Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of the 226,941 Series C Preferred Stock held by Takeda Ventures, Inc.